MedTrace Logo

AURORA: Crestor 10mg Versus Placebo in Subjects With End-stage Renal Disease (ESRD)

NCT00240331 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 2776

Last updated 2011-05-19

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to see if rosuvastatin helps to reduce the number of heart attacks, strokes and cardiovascular deaths in patients undergoing haemodialysis.

Conditions

  • Renal Failure

Interventions

DRUG

10mg Rosuvastatin

DRUG

Placebo

Sponsors & Collaborators

Principal Investigators

  • AstraZeneca Crestor Medical Sciences Director, MD · AstraZeneca

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-01-31
Primary Completion
2008-10-31
Completion
2008-10-31

Countries

  • Australia
  • Austria
  • Belgium
  • Brazil
  • Bulgaria
  • Canada
  • Czechia
  • Denmark
  • Finland
  • France
  • Germany
  • Greece
  • Hungary
  • Iceland
  • Ireland
  • Italy
  • Mexico
  • Netherlands
  • Norway
  • Poland
  • South Korea
  • Sweden
  • Switzerland
  • Turkey (Türkiye)
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00240331 on ClinicalTrials.gov